Results 1 to 10 of about 113,471 (74)

Identification and correction of systematic error in high-throughput sequence data. [PDF]

BMC Bioinformatics, 2011
Meacham F, Boffelli D, Dhahbi J, Martin DI, Singer M, Pachter L.   +5 more
europepmc   +1 more source

Assessment of predatory ability of native and non-native freshwater gammaridean species: A rapid test with water fleas as prey

Current Zoology, 2011
Predation rate with relation to species, sex and water temperature was tested among four different gammaridean species: Dikerogammarus villosus, Gammarus roeselii, Gammarus pulex and Gammarus fossarum.
B.E.M.W. STOFFELS, J.S. TUMMERS, G. VAN DER VELDE, D. PLATVOET, H.W.M. HENDRIKS, R.S.E.W. LEUVEN
doaj  

Modeling nest-survival data: a comparison of recently developed methods that can be implemented in MARK and SAS

Animal Biodiversity and Conservation, 2007
J. J. Rotella, S. J. Dinsmore, T. L Shaffer   +2 more
doaj   +1 more source

Aufruf zur Mitarbeit

Arachnologische Mitteilungen, 1994
Kreuels, Martin
doaj   +1 more source

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

Journal of Hematology and Oncology, 2023
Xiangcai Wang
exaly  

Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f® for ovarian stimulation: a phase-three trial

Reproductive BioMedicine Online, 2023
Feng Zhou
exaly  

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022
Jun Lu, Tianqing Chu, Yuqing Lou
exaly  

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial

Ophthalmology and Therapy, 2023
mengli zhu, Jian Ye, Jinglin Yi
exaly  

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors

Frontiers in Immunology, 2023
Zhiyu Huang, yanjun xu, Jing Qin
exaly